Cytophage Technologies (TSXV:CYTO) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cytophage Technologies's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cytophage Technologies could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Cytophage Technologies's Cash-to-Debt or its related term are showing as below:

TSXV:CYTO' s Cash-to-Debt Range Over the Past 10 Years
Min: 18.91 Med: 20.8 Max: No Debt
Current: 143

During the past 3 years, Cytophage Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 18.91. And the median was 20.80.

TSXV:CYTO's Cash-to-Debt is ranked better than
80.63% of 1528 companies
in the Biotechnology industry
Industry Median: 6.315 vs TSXV:CYTO: 143.00

Cytophage Technologies Cash-to-Debt Historical Data

The historical data trend for Cytophage Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cytophage Technologies Cash-to-Debt Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

18.91

20.80

No Debt

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Sep23	Dec23
Cash-to-Debt	18.91	N/A	20.80	12.45	No Debt

Competitive Comparison of Cytophage Technologies's Cash-to-Debt

For the Biotechnology subindustry, Cytophage Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Cash-to-Debt falls into.

Cytophage Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cytophage Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cytophage Technologies had no debt ⁽¹⁾.

Cytophage Technologies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cytophage Technologies had no debt ⁽¹⁾.

Cytophage Technologies (TSXV:CYTO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cytophage Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.